GALAPAGOS NV/S (NASDAQ:GLPG)’s share price was up 5.4% during mid-day trading on Friday . The company traded as high as $186.74 and last traded at $183.40, approximately 723,579 shares traded hands during trading. An increase of 456% from the average daily volume of 130,059 shares. The stock had previously closed at $174.01.
A number of analysts have recently commented on the company. ValuEngine raised XPO Logistics from a “strong sell” rating to a “sell” rating in a research note on Thursday, April 4th. Zacks Investment Research lowered ExlService from a “hold” rating to a “sell” rating in a research note on Wednesday, July 10th. Credit Suisse Group started coverage on LTC Properties in a research note on Wednesday, July 10th. They issued an “underperform” rating and a $19.00 price objective on the stock. BidaskClub lowered Weyco Group from a “sell” rating to a “strong sell” rating in a research note on Saturday, July 13th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Menlo Therapeutics in a research note on Thursday, May 2nd. Two equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company. GALAPAGOS NV/S presently has a consensus rating of “Buy” and an average price target of $148.10.
The firm has a market capitalization of $8.92 billion, a price-to-earnings ratio of -277.88 and a beta of 1.54. The firm has a fifty day simple moving average of $131.98. The company has a current ratio of 6.31, a quick ratio of 6.31 and a debt-to-equity ratio of 0.02.
GALAPAGOS NV/S (NASDAQ:GLPG) last issued its quarterly earnings data on Friday, April 26th. The biotechnology company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.19) by $0.18. GALAPAGOS NV/S had a negative return on equity of 3.60% and a negative net margin of 13.24%. The firm had revenue of $46.47 million during the quarter, compared to analyst estimates of $44.92 million. As a group, analysts expect that GALAPAGOS NV/S will post -4.4 EPS for the current year.
Institutional investors and hedge funds have recently modified their holdings of the company. Norges Bank purchased a new stake in GALAPAGOS NV/S in the fourth quarter valued at $6,422,000. Henry James International Management Inc. lifted its stake in shares of GALAPAGOS NV/S by 3.7% in the first quarter. Henry James International Management Inc. now owns 20,719 shares of the biotechnology company’s stock worth $2,440,000 after buying an additional 740 shares during the last quarter. Alps Advisors Inc. lifted its stake in shares of GALAPAGOS NV/S by 14.5% in the first quarter. Alps Advisors Inc. now owns 87,116 shares of the biotechnology company’s stock worth $10,261,000 after buying an additional 11,045 shares during the last quarter. OLD Mission Capital LLC lifted its stake in shares of GALAPAGOS NV/S by 103.2% in the fourth quarter. OLD Mission Capital LLC now owns 34,209 shares of the biotechnology company’s stock worth $3,138,000 after buying an additional 17,378 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in shares of GALAPAGOS NV/S by 14.6% in the fourth quarter. Millennium Management LLC now owns 72,538 shares of the biotechnology company’s stock worth $6,655,000 after buying an additional 9,217 shares during the last quarter. Hedge funds and other institutional investors own 16.32% of the company’s stock.
GALAPAGOS NV/S Company Profile (NASDAQ:GLPG)
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Featured Story: What is the accumulation/distribution indicator?
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.